2-Hydroxy-5-Methylpyridine CAS 1003-68-5 Purity ≥99.0% Pirfenidone Intermediate Factory

Short Description:

Chemical Name: 2-Hydroxy-5-Methylpyridine  

Synonyms: 5-Methyl-2(1H)-Pyridinone

CAS: 1003-68-5

Purity: ≥99.0%

Appearance: Off-White to Yellow Crystalline Powder

Intermediate of Pirfenidone (CAS: 53179-13-8) to treat Idiopathic Pulmonary Fibrosis (IPF)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production 
Chemical Name: 2-Hydroxy-5-Methylpyridine  
CAS: 1003-68-5

Chemical Properties:

Chemical Name 2-Hydroxy-5-Methylpyridine 
Synonyms 5-Methyl-2(1H)-Pyridinone; 2-Hydroxy-5-Picoline; 6-Hydroxy-3-Picoline; 5-Methyl-2-Pyridinol 
CAS Number 1003-68-5
CAT Number RF-PI549
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C6H7NO
Molecular Weight 109.13
Melting Point 183.0 to 187.0℃ (lit.)
Solubility Soluble in Methanol
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White to Yellow Crystalline Powder
Purity ≥99.0%
Moisture Content (K.F) ≤0.50%
Residue on Ignition ≤0.50%
Any Single Impurity ≤0.50%
Total Impurities ≤1.00%
Residual Solvents
n-Butanol ≤0.30%
Ethanol ≤0.30%
Test Standard Enterprise Standard
Usage Intermediate of Pirfenidone (CAS: 53179-13-8) 

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

2-Hydroxy-5-Methylpyridine (CAS: 1003-68-5) is used as a pharmaceutical intermediate of Pirfenidone (CAS: 53179-13-8). Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis.

  • Write your message here and send it to us